🌘 Kimi-K2.7-Code, our latest coding model, is now released and open-sourced! 🔷 Improved coding & agent performance over K2.6: 21.8% on Kimi Code Bench v2, 11.0% on Program Bench, and 31.5% on MLS Bench Lite. 🔷 Reasoning efficiency: Less overthinking, with 30% lower reasoning-token usage compared to K2.6. 🔷 Long-horizon coding: Improved instruction following, higher end-to-end coding task success rates. ⚡️ 6x High-Speed Mode coming soon! 🔌 Available today via Kimi API and Kimi Code. 🔗 Kimi Code: kimi.com/code 🔗 API: platform.moonshot.ai

MiniMax just updated the M3 license! Non-commercial use is now fully free. For commercial use: - Individuals or companies under $20M annual revenue only need to email them at api@minimax.io and add a “Build with MiniMax” label. - Only larger companies need to contact them for a full commercial license. This is actually pretty generous.

Arch Linux Now Believes Malware Incident Under Control: More Than 1,500 Affected Packages Wow! phoronix.com/news/Arch-Linux…

I had it in ultra-code mode and it treated the ask as a "substantive task" and spawned 10 agents, which then autonomously scaled to 56. And since Fable 5 was the session model, every sub-agent inherited it burning at maximum rate. 1.5M tokens in under 12 minutes. The workflow had 4 phases: 1. Research - 1 agent 2. Map - deep-read all 25 scenarios (multiple map agents) 3. Critique - 6 independent lens agents, each returning a list of findings 4. Verify - adversarial verification of every finding from all 6 lenses That last phase is the explosion. Each of the 6 critique agents returned multiple findings, and the verify phase spawned a separate agent for every individual finding across all lenses.

‼️🚨 MAJOR OPSEC FAIL by controversial Israeli spyware company NSO Group. They uploaded an image of a desktop mat displaying their own company's logo. WhatsApp court documents show the group created test accounts and groups on WhatsApp, despite receiving a permanent injunction that barred them from ever targeting WhatsApp and its users.

FORBES: The New Billionaire Bet Isn't AI — It's Longevity Biotech forbes.com/sites/dariashunin…

🚨 BREAKING: More than 400 Arch Linux User Repository packages have been compromised with infostealer malware and a rootkit. Attacker posed as a trusted maintainer and "adopted" orphaned packages. Arch maintainers are purging infected packages now. Audit your AUR installs.

I'm 38. At this point of my life/career, I have so many friends working corporate W2 jobs making $200-400K/year (mostly in NYC/NJ/PA corridor) who just don't actually work that much. One friend makes $250K as a manager at a biotech... all he does is send pictures of his chicken coop or other DIY projects all day during the week.. no idea what value he actually provides his company. Then there's my "jiggler" friend who you might recall... guy makes $250-300K and just plugs a "mouse jiggler" into his laptop and just goes to the gym, homeschools his kids, tans, does yard work... all day. I ask him what he does and he can't even articulate it... Another friend makes $150K at a remote startup and just travels around the world all the time... don't ask don't tell situation on where people are at any given time... but does seemingly little actual work.. maybe 1 hour a day. This is truly what's going on out there... BS W2 jobs all over the place. And AI is a bubble? Really?

Quasar is entering its next chapter on Bittensor SN24. We are moving toward a 10T-token decentralized training run. The idea is simple Quasar Models needs more useful training, not just bigger parameter counts. Real model quality comes from tokens, data quality, training direction, and the ability to keep improving checkpoint by checkpoint. This run starts with a 5T-token phase to produce a stronger checkpoint, then continues into another 5T-token phase, reaching 10T total trained tokens. SN24 will set the direction: the starting checkpoint, the data, the training recipe, and the evaluation system. Miners become the extra compute layer. They help Quasar train faster, improve continuously, and move forward together. this would be the largest token-scale training runs ever attempted in decentralized AI. This is how we scale Quasar. Help us train it 👇

are you paying attention chad? the anti-aging and human enhancement arms race just went geopolitical - Russia committed $26B. Putin made longevity a Kremlin priority. organ printing, genetics, cryotherapy. - China published a 5-year national biotech plan. gene therapy, BCIs, AI drug discovery. genuine human firsts, not me-too drugs. - UAE launched a national longevity program backed by sovereign wealth. zero taxes. fastest clinical trial approvals in the world. - Singapore is funding longevity research at the state level and recruiting the world's best biotech founders. and the private sector is not waiting - Life Biosciences just injected the first reverse-aging drug into a human - NewLimit raised $435M from Peter Thiel's Founders Fund. Brian Armstrong's bet on age reprogramming is moving from lab to clinic. - Retro Biosciences raised $1.8B. Sam Altman's bet on adding 10 healthy years to human lifespan is scaling. - Isomorphic Labs raised $2.1B. Demis Hassabis betting AI designs drugs better than humans. - Neuralink has 21 implants in humans. Merge Labs launched with $252M. the BCI race is real. - Altos Labs. $3B from Bezos. cellular rejuvenation. the largest single longevity round ever. every major power and every serious founder on earth is pointing at the same problem the race has begun bio/acc

More AI-generated code doesn't make your team faster. It might actually slow you down.

David Sinclair's lab is starting the first FDA-approved anti-aging clinical trial in humans. The therapy (ER-100) is a type of cellular reprogramming that uses 3 Yamanaka factors - OCT4, SOX2, and KLF4 (OSK) Their earlier mouse studies have shown benefits in restoring vision after optic nerve injury, glaucoma, and age-related decline. 🧵👇 Video breakdown: youtu.be/lY-43-HD-mA

im dying laughing

plenty of distros (and users) do this because docker daemon access = root unfortunately

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

You're not even allowed to ask Fable about basic biology questions, let alone anything that could potentially be dangerous.